What Irgasan DP300 treats: main uses and benefits

As an antimicrobial agent, Irgasan DP300 is relevant for easing symptoms that are linked to localized microbial proliferation and is applied in contexts where additional symptomatic support is needed, such as in high-risk medical scenarios. The use of antimicrobial triclosan-coated materials is relevant in clinical contexts where additional support for reducing the risk of surgical site infection is needed.

Irgasan DP300 helps address conditions presenting with localized discomfort, including gingivitis, dental plaque accumulation, minor abrasions, and contexts involving the management of high-risk organisms on the skin. This use assists with maintaining stability by contributing to easing the overall symptom load related to microbial presence. The substance is used across therapeutic domains where short-term symptom management is appropriate, such as when symptoms related to inflammatory or irritative states occur.

“It is commonly used to help with managing symptoms that interfere with daily comfort, particularly those associated with microbial overgrowth.”

---

Quick Fact: Support for Localized Microbial Symptoms

Irgasan DP300 is commonly used to help manage symptoms such as gum bleeding and inflammation associated with plaque, as well as to support a reduced microbial environment in clinical settings.

The official eligibility profile for Irgasan DP300 (Triclosan) is defined by the specific product type, concentration, and authoritative regulatory classification.

Contraindications and Prohibited Use

Use is absolutely contraindicated for any patient with a known allergy or hypersensitivity to triclosan or any component in the formulation. Furthermore, the use of triclosan in over-the-counter (OTC) consumer antiseptic wash products (such as hand soaps) is prohibited by the FDA, as these ingredients are officially ruled not Generally Recognized As Safe and Effective (GRASE) for long-term daily use.

Age-Specific and Conditional Eligibility

Population Group	Eligibility Status (Regulatory Basis)
Adults	Use is permitted in highly regulated applications, such as specific concentrations in toothpaste (e.g., 0.3%) or controlled healthcare antiseptics.
Children & Adolescents	Eligibility is generally restricted, as safety and effectiveness are often not established for the general pediatric population. European regulatory advice specifically notes that use in mouthwash is not recommended for this age group.
Pregnant & Nursing Women	Use is considered conditional and requires caution, primarily due to the documented presence of the substance in human cord blood and breast milk.

All authorized use is strictly limited to topical or mucosal application, as defined in official prescribing information.

Interactions with other medicines and products

The official regulatory profile for Irgasan DP300 (Triclosan) interactions is primarily structured by its intended use as a topical or mucosal agent, which leads to minimal systemic absorption. This characteristic results in very limited formal pharmacokinetic drug-drug interactions being documented in authoritative government sources.

Local and Systemic Interaction Patterns

Interaction Type	Interacting Agent	Official Regulatory Statement
Pharmacodynamic	Other topical antiseptic agents or disinfectants	Co-administration may lead to additive or antagonistic local effects, potentially altering efficacy or increasing local irritation.
Pharmacokinetic	Substrates of CYP2C9 and CYP3A4 enzymes	The active ingredient shows in vitro potential for CYP enzyme inhibition, which theoretically could increase plasma levels of co-administered substrates.

Interaction Classification and Constraints

Regulatory documents consistently classify the theoretical pharmacokinetic risk (CYP inhibition) as not clinically significant for approved topical use, as systemic exposure is negligible. Therefore, no mandatory timing separation rules or formal contraindications with systemic medications are established in official labeling based on pharmacokinetic interaction risk. The primary constraint specified in regulatory texts is the caution against co-use with other local antiseptics due to the potential for pharmacodynamic interference. No specific interactions with food, alcohol, or herbal products are formally documented.

Irgasan DP300, chemically triclosan, operates via a dual-action mechanism dependent on its concentration. At lower, bacteriostatic concentrations, triclosan penetrates the bacterial cell wall and membrane to accumulate in the cytoplasm. Its primary molecular target is the enoyl-acyl carrier protein reductase (ENR) enzyme, encoded by the fabI gene, which is a key component of the bacterial type II fatty acid synthesis (FAS-II) pathway.

Triclosan acts as an inhibitor by binding tightly to the active site of ENR. This binding increases the enzyme's affinity for nicotinamide adenine dinucleotide ( NAD^+), resulting in the formation of a stable, non-functional ternary complex: ENR-NAD^+-triclosan. The formation of this complex blocks the reduction of enoyl-ACP, effectively arresting the FAS-II pathway. The intracellular consequence is the cessation of essential fatty acid synthesis, which are required for the construction and repair of the bacterial cytoplasmic membrane and cell growth. The systemic physiological consequence is the arrest of bacterial proliferation.

At higher, bactericidal concentrations, the lipophilic triclosan accumulates extensively within the bacterial lipid bilayer. This molecular interaction causes direct disruption of membrane integrity, leading to a non-specific leakage of intracellular constituents, precipitating rapid cell death.

Irgasan DP300 (Triclosan) is a localized antimicrobial agent. Administration is limited to topical application on the skin and mucosal application within the oral cavity, which means the product is never intended for systemic ingestion.

This substance is supplied in liquid solutions for topical washes and as pastes or gels for specific oral hygiene uses. Dosage strengths for topical liquids typically range from 0.115% to 0.6%, while the concentration for certain oral products is 0.3%.

The dosing schedule varies based on context. For oral care, the use is generally set at twice daily as part of a long-term maintenance regimen. In contrast, topical cleansing applications are used on an intermittent or as-needed basis.

Administration requires specific preparation and rinsing steps. Topical solutions must be mixed with water to create a lather before being applied. All administration protocols require the application site to be rinsed thoroughly with water immediately following use. This procedural step ensures the substance is removed after the necessary contact time. Instructions do not typically include specific dose adjustments for older adults or patients with renal or hepatic impairment due to the drug’s localized action.

Irgasan DP300: Recent Clinical Evidence

Irgasan DP300 is the trade name for the broad-spectrum antimicrobial agent Triclosan (TCS). Research into this compound focuses on its effectiveness in hygiene applications and its potential effects on human and environmental health, particularly following its widespread use in consumer products.

---

Effectiveness in Hygiene and Medical Settings

Clinical data has explored the compound's use in various formulations. In a hospital setting, it was historically employed as a surgical scrub and is noted for providing an immediate and persistent antimicrobial effect on the skin. Studies comparing Triclosan-containing soaps with plain soap and water for handwashing in non-healthcare environments have generally found that Triclosan does not provide a proven benefit over the use of regular soap and water for reducing the spread of infection.

An exception where benefit has been identified is in adult toothpaste formulations, where the addition of Triclosan has been documented to help slow bacterial decay and aid in preventing gingivitis.

---

Safety and Regulatory Concerns

The extensive use of Triclosan has led to its detection in various human body fluids, including urine and breast milk, prompting regulatory review and ongoing health research. The following areas have been a focus of recent studies:

• Endocrine Disruption: Research, primarily in animal models, suggests that Triclosan may interact with the body's hormone systems, including thyroid and sex hormones. Epidemiological studies in humans concerning these effects remain inconsistent.
• Antibiotic Resistance: Concerns have been raised that the widespread use of Triclosan, even at low concentrations, may contribute to the emergence of antibiotic-resistant bacteria.
• Skin Reactions: While generally well-tolerated in formulated products, rare cases of contact dermatitis have been reported with its use.

Common questions about Irgasan DP300 (FAQ)

Q: Is Irgasan DP300 (Triclosan) freely soluble in water, and what is its chemical classification (e.g., is it an antimicrobial or an antibiotic)?

Triclosan is generally described in technical documents as only slightly soluble in water but readily dissolves in other solvents. Its official pharmacological classification is an Antimicrobial Agent and Biocide, which means it has a broad range of activity against microorganisms like bacteria and some fungi. In formal classification, it is considered an antiseptic and disinfectant, which avoids the clinical implications associated with the term 'antibiotic' used for systemic medications.

Q: Has Triclosan been classified as a Persistent Organic Pollutant (POP) by an official government body?

Triclosan has been listed in some regulatory documents as a xenobiotic and a persistent organic pollutant (POP). This classification relates to its resistance to breaking down and its tendency to accumulate in the environment. Due to these characteristics, it is often designated as a 'contaminant of emerging concern' by environmental safety bodies.

Q: What is the official regulatory status of Triclosan's use in cosmetic products in the EU and USA?

Regulatory actions have placed significant restrictions on Triclosan. The US FDA banned its use in most over-the-counter consumer antiseptic wash products in 2016. In the EU, it is listed as a preservative in cosmetic products under Annex V of the Cosmetics Regulation, but its use is subject to strict concentration limits and ongoing review due to endocrine disruption concerns.

Q: Is there an official regulatory warning or classification concerning Triclosan's link to cancer?

Regulatory research from bodies like the US National Toxicology Program has investigated the potential link between Triclosan and cancer. Studies conducted in animal models suggested some evidence of carcinogenic activity in male mice. It is important to note that these findings relate to animal data, and human risk assessment remains an area of ongoing focus.

Q: Are children exposed to Triclosan through treated surfaces (toys, kitchenware) and what are the documented consequences of such exposure?

Triclosan can be incorporated into various materials like toys or textiles, but this is classified as a pesticidal use, not a drug or cosmetic use. Specific health consequences related to touching these treated surfaces are not generally detailed in official drug or cosmetic regulatory labels, because these types of products fall outside the jurisdiction of drug regulation.

Official Storage and Disposal Requirements

Storage of Irgasan DP300 (Triclosan) products must adhere strictly to labeled regulatory conditions to maintain stability and ensure safety.

Requirement Type	Official Labeled Condition
Temperature	Store at controlled room temperature, typically 20 C to 25 C.
Prohibited Environment	Do not freeze and protect from excessive heat.
Packaging	Keep container tightly closed and store in the original container.
Child Safety	Keep out of the sight and reach of children.

Disposal of Unused Product

Official instructions require that unused or expired product be handled responsibly. Dispose of unused product according to local regulations for pharmaceutical or chemical waste. It is mandatory to avoid releasing the product into the environment, which means do not pour or flush it into household wastewater systems.